Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study.
chronic kidney disease
end-stage kidney disease
haemodialysis
peritoneal dialysis
phosphate binder
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
01
07
2020
entrez:
5
7
2021
pubmed:
6
7
2021
medline:
6
7
2021
Statut:
epublish
Résumé
The iron-based phosphate binder (PB), sucroferric oxyhydroxide (SFOH), is indicated to control serum phosphorus levels in patients with chronic kidney disease on dialysis. This non-interventional, prospective, multicentre, cohort study conducted in seven European countries evaluated the safety and effectiveness of SFOH in dialysis patients with hyperphosphataemia in routine practice. Safety outcomes included adverse drug reactions (ADRs) and changes in iron-related parameters. SFOH effectiveness was evaluated by changes-from-baseline (BL) in serum phosphorus and percentage of patients achieving in-target phosphorus levels. The safety analysis set included 1365 patients (mean observation: 420.3 ± 239.3 days). Overall, 682 (50.0%) patients discontinued the study. Mean SFOH dose during the observation period was 1172.7 ± 539.9 mg (2.3 pills/day). Overall, 617 (45.2%) patients received concomitant PB(s) during SFOH treatment. ADRs and serious ADRs were observed for 531 (38.9%) and 26 (1.9%) patients. Most frequent ADRs were diarrhoea (194 patients, 14.2%) and discoloured faeces (128 patients, 9.4%). Diarrhoea generally occurred early during SFOH treatment and was mostly mild and transient. Small increases from BL in serum ferritin were observed (ranging from +12 to +75 µg/L). SFOH treatment was associated with serum phosphorus reductions (6.3 ± 1.6 mg/dL at BL versus 5.3 ± 1.8 mg/dL at Month 30; ΔBL: -1.0 mg/dL, P < 0.01). Percentage of patients achieving serum phosphorus ≤4.5 mg/dL increased from 12.0% at BL to 34.8% at Month 30, while the percentage achieving serum phosphorus ≤5.5 mg/dL increased from 29.9% to 63.0%. SFOH has a favourable safety and tolerability profile in a real-world setting, consistent with results of the Phase 3 study. Moreover, SFOH improved serum phosphorus control with a low daily pill burden.
Sections du résumé
BACKGROUND
BACKGROUND
The iron-based phosphate binder (PB), sucroferric oxyhydroxide (SFOH), is indicated to control serum phosphorus levels in patients with chronic kidney disease on dialysis.
METHODS
METHODS
This non-interventional, prospective, multicentre, cohort study conducted in seven European countries evaluated the safety and effectiveness of SFOH in dialysis patients with hyperphosphataemia in routine practice. Safety outcomes included adverse drug reactions (ADRs) and changes in iron-related parameters. SFOH effectiveness was evaluated by changes-from-baseline (BL) in serum phosphorus and percentage of patients achieving in-target phosphorus levels.
RESULTS
RESULTS
The safety analysis set included 1365 patients (mean observation: 420.3 ± 239.3 days). Overall, 682 (50.0%) patients discontinued the study. Mean SFOH dose during the observation period was 1172.7 ± 539.9 mg (2.3 pills/day). Overall, 617 (45.2%) patients received concomitant PB(s) during SFOH treatment. ADRs and serious ADRs were observed for 531 (38.9%) and 26 (1.9%) patients. Most frequent ADRs were diarrhoea (194 patients, 14.2%) and discoloured faeces (128 patients, 9.4%). Diarrhoea generally occurred early during SFOH treatment and was mostly mild and transient. Small increases from BL in serum ferritin were observed (ranging from +12 to +75 µg/L). SFOH treatment was associated with serum phosphorus reductions (6.3 ± 1.6 mg/dL at BL versus 5.3 ± 1.8 mg/dL at Month 30; ΔBL: -1.0 mg/dL, P < 0.01). Percentage of patients achieving serum phosphorus ≤4.5 mg/dL increased from 12.0% at BL to 34.8% at Month 30, while the percentage achieving serum phosphorus ≤5.5 mg/dL increased from 29.9% to 63.0%.
CONCLUSIONS
CONCLUSIONS
SFOH has a favourable safety and tolerability profile in a real-world setting, consistent with results of the Phase 3 study. Moreover, SFOH improved serum phosphorus control with a low daily pill burden.
Identifiants
pubmed: 34221384
doi: 10.1093/ckj/sfaa211
pii: sfaa211
pmc: PMC8243278
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1770-1779Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA.
Références
Nat Rev Nephrol. 2011 Sep 06;7(10):578-89
pubmed: 21894188
Kidney Int. 2014 Sep;86(3):638-47
pubmed: 24646861
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Hemodial Int. 2016 Jan;20(1):38-49
pubmed: 25975222
Am J Kidney Dis. 2018 Nov;72(5):634-643
pubmed: 30146421
Clin Nephrol. 2014 Apr;81(4):251-8
pubmed: 24656315
Kidney Int Rep. 2019 Jun 20;4(8):1043-1056
pubmed: 31440695
J Nephrol. 2010 Sep-Oct;23(5):525-34
pubmed: 20119931
Nephrol Dial Transplant. 2013 Jul;28(7):1922-35
pubmed: 23166310
Nephrol Dial Transplant. 2017 Aug 1;32(8):1330-1338
pubmed: 27342579
J Am Soc Nephrol. 2004 Aug;15(8):2208-18
pubmed: 15284307
Am J Kidney Dis. 1998 Apr;31(4):607-17
pubmed: 9531176
Nephrol Dial Transplant. 2015 Jun;30(6):1037-46
pubmed: 25691681
Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201
pubmed: 14520607
Nephrol Dial Transplant. 2019 Apr 1;34(4):673-681
pubmed: 29741651
J Am Soc Nephrol. 2001 Oct;12(10):2131-2138
pubmed: 11562412
Kidney Int. 2013 Nov;84(5):998-1008
pubmed: 23823605
Clin J Am Soc Nephrol. 2013 Feb;8(2):280-9
pubmed: 23124782
J Clin Hypertens (Greenwich). 2008 May;10(5):348-54
pubmed: 18453793